NASDAQ : ADAG
Adagene Inc. — Key statistics
Healthcare · Biotechnology · China
Last price 2.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 168.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 168.53M |
| Enterprise Value | 46.71M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 67.14M |
| Shares Change (YoY) | +11.73% |
| Shares Change (QoQ) | +19.71% |
| Owned by Insiders (%) | 10.11% |
| Owned by Institutions (%) | 43.21% |
| Float | 44.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.14 |
| Forward PS | n/a |
| PB Ratio | 1.88 |
| P/TBV Ratio | 1.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.02 |
| Quick Ratio | 4.86 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -78.36 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -28.50% |
| Return on Assets (ROA) | -13.95% |
| Return on Invested Capital (ROIC) | -17.80% |
| Return on Capital Employed (ROCE) | -20.83% |
| Weighted Average Cost of Capital (WACC) | 7.71% |
| Revenue Per Employee | $72,584 |
| Profits Per Employee | -$160,242 |
| Employee Count | 128 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -366,334 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.66 |
| 52-Week Price Change | +36.41% |
| 50-Day Moving Average | 3.05 |
| 200-Day Moving Average | 3.42 |
| Relative Strength Index (RSI) | 43.54 |
| Average Volume (20 Days) | 327,805 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.12M |
| Short Previous Month | 2.11M |
| Short % of Shares Out | 3.70% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.48 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 9.29M |
| Gross Profit | 9.29M |
| Operating Income | -22.34M |
| Pretax Income | -20.88M |
| Net Income | -20.51M |
| EBITDA | -21.95M |
| EBIT | -22.34M |
| Loss Per Share | -$0.39 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 127.91M |
| Total Debt | 6.09M |
| Net Cash | 121.82M |
| Net Cash Per Share | $1.81 |
| Equity (Book Value) | 106.00M |
| Book Value Per Share | 1.33 |
| Working Capital | 106.05M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.25M |
| Capital Expenditures | -170,783 |
| Depreciation & Amortization | 384,223 |
| Net Borrowing | -1.21M |
| Free Cash Flow | -19.42M |
| FCF Per Share | -$0.29 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -240.42% |
| Pretax Margin | -224.71% |
| Profit Margin | -220.77% |
| EBITDA Margin | -236.28% |
| EBIT Margin | -240.42% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.73% |
| Shareholder Yield | n/a |
| Earnings Yield | -15.73% |
| FCF Yield | -11.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.91 |
| Price Target Difference | 294.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | -16.29% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.08 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |